The Comparative Effectiveness of PDE5 Inhibitors and β3 Agonists Versus α-Blockers in Medical Expulsive Therapy for Distal Ureteric Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]
CureusRamanah M +5 more
europepmc +1 more source
Differential Risks of Dementia, Depression, and Injury Among Common α-Blockers, with Tamsulosin as the Reference Drug: A Real-World Cohort Study in Men with Lower Urinary Tract Symptoms. [PDF]
J Clin MedChen SS +4 more
europepmc +1 more source
Drug- and patient-specific neurological risk profiles of α1-adrenergic blockers: evidence from FAERS and external validation in JADER. [PDF]
Ther Adv Drug SafHai X, Huang L.
europepmc +1 more source
Modulation of Mesangial Cells by Tamsulosin and Pioglitazone Under Hyperglycemic Conditions: An In Vitro and In Vivo Study. [PDF]
Int J Mol SciAguilera-Martínez SL +4 more
europepmc +1 more source
Ureteral stent symptoms: A systematic review and meta-analysis comparing the use of mirabegron and tamsulosin. [PDF]
BJUI CompassMadarshahian D +4 more
europepmc +1 more source
Microbiota composition and intestinal barrier function modulated by tamsulosin and <i>Lactococcus lactis</i> in a cirrhosis rat model. [PDF]
Front Cell Infect MicrobiolPadilla-García SV +5 more
europepmc +1 more source
Mirabegron Versus Tamsulosin in Reducing Double-J Stent-Related Symptoms: A Prospective Comparative Study. [PDF]
CureusPatil SR +3 more
europepmc +1 more source
Double versus standard dose of tamsulosin with solifenacin for management of ureteral stent related symptoms. [PDF]
Arab J UrolHefnawy A +4 more
europepmc +1 more source
Impact of Fixed-Dose Combination Versus Single-Component Therapy for Benign Prostatic Hyperplasia-Related Urinary Symptoms on Persistence, Adherence, and Satisfaction in a Real-Life Setting. [PDF]
Pharmaceuticals (Basel)Małkowski M +4 more
europepmc +1 more source